Accelerating Product Innovation and Availability

Improving how prevention is delivered

Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.

Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.

AVAC’s work supports:

The Latest on Accelerating Product Innovation

Event

Update on Injectable Lenacapavir for PrEP

SAVE THE DATE: Join AVAC, Gilead and partners for a discussion of and comprehensive presentation on lenacapavir for PrEP data from the PURPOSE I and II trials, along with an update on where we are with global access and regulatory submissions.

More details, including registration, to come.